FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209345071> ?p ?o ?g. }

• W3209345071 endingPage "2949" @default.
• W3209345071 startingPage "2949" @default.
• W3209345071 abstract "The first quarter of the 21st century has remarkably been characterized by a multitude of challenges confronting human society as a whole in terms of several outbreaks of infectious viral diseases, such as the 2003 severe acute respiratory syndrome (SARS), China; the 2009 influenza H1N1, Mexico; the 2012 Middle East respiratory syndrome (MERS), Saudi Arabia; and the ongoing coronavirus disease 19 (COVID-19), China. COVID-19, caused by SARS-CoV-2, reportedly broke out in December 2019, Wuhan, the capital of China's Hubei province, and continues unabated, leading to considerable devastation and death worldwide. The most common target organ of SARS-CoV-2 is the lungs, especially the bronchial and alveolar epithelial cells, culminating in acute respiratory distress syndrome (ARDS) in severe patients. Nevertheless, other tissues and organs are also known to be critically affected following infection, thereby complicating the overall aetiology and prognosis. Excluding H1N1, the SARS-CoV (also referred as SARS-CoV-1), MERS, and SARS-CoV-2 are collectively referred to as coronaviruses, and taxonomically placed under the realm Riboviria, order Nidovirales, suborder Cornidovirineae, family Coronaviridae, subfamily Orthocoronavirinae, genus Betacoronavirus, and subgenus Sarbecovirus. As of 23 September 2021, the ongoing SARS-CoV-2 pandemic has globally resulted in around 229 million and 4.7 million reported infections and deaths, respectively, apart from causing huge psychosomatic debilitation, academic loss, and deep economic recession. Such an unprecedented pandemic has compelled researchers, especially epidemiologists and immunologists, to search for SARS-CoV-2-associated potential immunogenic molecules to develop a vaccine as an immediate prophylactic measure. Amongst multiple structural and non-structural proteins, the homotrimeric spike (S) glycoprotein has been empirically found as the most suitable candidate for vaccine development owing to its immense immunogenic potential, which makes it capable of eliciting both humoral and cell-mediated immune responses. As a consequence, it has become possible to design appropriate, safe, and effective vaccines, apart from related therapeutic agents, to reduce both morbidity and mortality. As of 23 September 2021, four vaccines, namely, Comirnaty, COVID-19 vaccine Janssen, Spikevax, and Vaxzevria, have received the European Medicines Agency's (EMA) approval, and around thirty are under the phase three clinical trial with emergency authorization by the vaccine-developing country-specific National Regulatory Authority (NRA). In addition, 100-150 vaccines are under various phases of pre-clinical and clinical trials. The mainstay of global vaccination is to introduce herd immunity, which would protect the majority of the population, including immunocompromised individuals, from infection and disease. Here, we primarily discuss category-wise vaccine development, their respective advantages and disadvantages, associated efficiency and potential safety aspects, antigenicity of SARS-CoV-2 structural proteins and immune responses to them along with the emergence of SARS-CoV-2 VOC, and the urgent need of achieving herd immunity to contain the pandemic." @default.
• W3209345071 created "2021-11-08" @default.
• W3209345071 creator A5019752480 @default.
• W3209345071 creator A5021505731 @default.
• W3209345071 creator A5021518210 @default.
• W3209345071 creator A5031413322 @default.
• W3209345071 creator A5037976340 @default.
• W3209345071 creator A5041910922 @default.
• W3209345071 creator A5046645647 @default.
• W3209345071 creator A5047305386 @default.
• W3209345071 creator A5055256247 @default.
• W3209345071 creator A5061006768 @default.
• W3209345071 creator A5066778845 @default.
• W3209345071 creator A5073399094 @default.
• W3209345071 creator A5074937522 @default.
• W3209345071 creator A5075936636 @default.
• W3209345071 date "2021-10-29" @default.
• W3209345071 modified "2023-10-09" @default.
• W3209345071 title "Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity" @default.
• W3209345071 cites W1515031832 @default.
• W3209345071 cites W1534923950 @default.
• W3209345071 cites W190626844 @default.
• W3209345071 cites W1910947906 @default.
• W3209345071 cites W1972381161 @default.
• W3209345071 cites W2000177767 @default.
• W3209345071 cites W2000920812 @default.
• W3209345071 cites W2004583429 @default.
• W3209345071 cites W2012151421 @default.
• W3209345071 cites W2020052970 @default.
• W3209345071 cites W2031164321 @default.
• W3209345071 cites W2033299041 @default.
• W3209345071 cites W2065818546 @default.
• W3209345071 cites W2066728093 @default.
• W3209345071 cites W2091129202 @default.
• W3209345071 cites W2092237558 @default.
• W3209345071 cites W2103753861 @default.
• W3209345071 cites W2117002055 @default.
• W3209345071 cites W2117549098 @default.
• W3209345071 cites W2122718880 @default.
• W3209345071 cites W2125382661 @default.
• W3209345071 cites W2141669350 @default.
• W3209345071 cites W2149401383 @default.
• W3209345071 cites W2160358721 @default.
• W3209345071 cites W2161150914 @default.
• W3209345071 cites W2163448677 @default.
• W3209345071 cites W2165039106 @default.
• W3209345071 cites W2232037017 @default.
• W3209345071 cites W2318349818 @default.
• W3209345071 cites W2410344917 @default.
• W3209345071 cites W2418601731 @default.
• W3209345071 cites W2555838982 @default.
• W3209345071 cites W2564296980 @default.
• W3209345071 cites W2593435098 @default.
• W3209345071 cites W2606148195 @default.
• W3209345071 cites W2756483320 @default.
• W3209345071 cites W2770844838 @default.
• W3209345071 cites W2782708334 @default.
• W3209345071 cites W2783642412 @default.
• W3209345071 cites W2891486793 @default.
• W3209345071 cites W2900898034 @default.
• W3209345071 cites W2935370752 @default.
• W3209345071 cites W2936804536 @default.
• W3209345071 cites W2971640287 @default.
• W3209345071 cites W3002108456 @default.
• W3209345071 cites W3002539152 @default.
• W3209345071 cites W3004280078 @default.
• W3209345071 cites W3004318991 @default.
• W3209345071 cites W3006703916 @default.
• W3209345071 cites W3008028633 @default.
• W3209345071 cites W3009232636 @default.
• W3209345071 cites W3009335299 @default.
• W3209345071 cites W3009983851 @default.
• W3209345071 cites W3012195391 @default.
• W3209345071 cites W3012844399 @default.
• W3209345071 cites W3013853564 @default.
• W3209345071 cites W3016655948 @default.
• W3209345071 cites W3018013720 @default.
• W3209345071 cites W3020062806 @default.
• W3209345071 cites W3021590963 @default.
• W3209345071 cites W3022285953 @default.
• W3209345071 cites W3022917947 @default.
• W3209345071 cites W3023443343 @default.
• W3209345071 cites W3024521757 @default.
• W3209345071 cites W3024541652 @default.
• W3209345071 cites W3025320502 @default.
• W3209345071 cites W3025520348 @default.
• W3209345071 cites W3025521550 @default.
• W3209345071 cites W3025987322 @default.
• W3209345071 cites W3027138240 @default.
• W3209345071 cites W3027204812 @default.
• W3209345071 cites W3027348102 @default.
• W3209345071 cites W3030537287 @default.
• W3209345071 cites W3032859583 @default.
• W3209345071 cites W3033950875 @default.
• W3209345071 cites W3034173374 @default.
• W3209345071 cites W3034816694 @default.
• W3209345071 cites W3035767992 @default.
• W3209345071 cites W3036529319 @default.

• next